Search

Refine your search

Content type
Tags
Firm name
Author
Jurisdiction
Language

1,221 results found

Article

Kilpatrick Townsend & Stockton LLP | European Union, Global, United Kingdom, etc. | 11 Feb 2021

Should We Require Human Inventorship? Submit Your Amicus Brief by March

A variety of artificial intelligence (AI) technologies exist and are being used in biopharma (e.g., discovery and development of drugs, optimization…
Article

Kilpatrick Townsend & Stockton LLP | USA | 21 Dec 2020

Is compulsory licensing the right tool that will allow the executive branch to control drug pricing?

Prescription drug prices, and means by which the Executive Branch might reduce them absent legislative action, were a hot topic during the 2020…
Article

Kramer Levin Naftalis & Frankel LLP | USA | 30 Nov 2020

Third-Generation Vaccines Take Center Stage in Battle Against COVID-19

The biopharmaceutical industry is at the forefront of COVID-19 news due to major advances in vaccine development. Now, more than a year since the…
Article

Carpmaels & Ransford LLP | European Union | 26 Jun 2020

How the COVID-19 Pandemic can disrupt life sciences patenting and what you can do about it

The COVID-19 pandemic has caused severe disruptions to many businesses around the world. Pharmaceutical and biotechnology companies have perhaps felt…
Article

LexOrbis | India | 2 Jun 2020

Trends in biopharma and biosimilar patents in India

Legal protection for IP rights in the science and technology domain is a topic of long debate around the world, particularly regarding those…
Article

Kramer Levin Naftalis & Frankel LLP | USA | 29 Apr 2020

Biopharma Develops Antibody and Stem Cell Therapies in the Fight Against COVID-19

SARS-CoV-2, the virus that causes COVID-19, is a novel coronavirus never before seen in humans. To date, it has caused 60,000 deaths in the United…
Article

Kramer Levin Naftalis & Frankel LLP | USA | 8 Apr 2020

BioPharma Develops Needed RNA and Antibody Tests for COVID-19

SARS-CoV-2, the virus that causes COVID-19, has been called an “invisible enemy.” It has spread through communities and across the globe, thanks in…
Article

Kramer Levin Naftalis & Frankel LLP | USA | 6 Apr 2020

Biopharmaceutical Industry Fights COVID-19 Pandemic with Innovation and Speed

The COVID-19 pandemic has created unprecedented challenges for almost every industry. Most acute is the clinical challenge facing overwhelmed and…
Analysis PRO In-house

PRO Compliance | European Union | 25 Mar 2020

EU opens investigation into Johnson & Johnson deal with Takeda

The European Commission has opened an in-depth investigation into Johnson & Johnson’s proposed acquisition of Takeda's surgical patch product.
Article

Baker McKenzie | USA | 18 Dec 2019

Guide to IPOs for biotech and pharma companies

Biotech and pharma companies undertaking capital raisings can approach the world's capital markets in various ways. Through an initial public…
Previous page 1 2 3 ...